Our own recent work identified inhibition of GAPDH and aerobic glycolysis as a key therapeutic mechanism of dimethyl fumarate (DMF), which is a clinically approved immunomodulatory drug used in the treatment of MS (Kornberg et al., 2018). The gene discussed is GAPDH; the disease is myeloid sarcoma.